首页 > 最新文献

Biomedical Journal最新文献

英文 中文
High-fat diet-induced increase in glucocorticoids contributes to adipogenesis in obese mice. 高脂饮食引起的糖皮质激素增加有助于肥胖小鼠的脂肪生成。
IF 4.1 3区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-22 DOI: 10.1016/j.bj.2024.100772
Sheng-Feng Tsai, Pei-Ling Hsu, Mei-Chen Yeh, Hao-Chang Hung, Monica Meng-Chun Shih, Bon-Chu Chung, Chia-Yih Wang, Chih-Jen Chang, Yu-Min Kuo

Background: This study was designed to examine how glucocorticoids (GCs) induced by a long-term ingestion of high-fat diet (HFD) mediate the HFD-induced adipose expansion and obesity.

Material and methods: To address this goal, we used a unique L/L mouse model that fails to induce its corticosterone (CORT) level, a major type of GCs in rodents, after prolonged exposure to an HFD.

Results: We found that, after receiving a 12-week HFD feeding, the L/L mice show less weight gain, milder adipose expansion, and higher plasma levels of triglycerides than the wild-type mice. These changes were reversed by replenishing CORT to L/L mice. When examining the expression levels of various molecules linked to lipid uptake and de novo lipogenesis in CORT-induced adipose expansion, we observed a reduction in the expression of adipose preadipocyte factor 1 (Pref-1), a key regulator in adipogenesis. In 3T3-L1 preadipocyte-like cells, dexamethasone, an agonist of the glucocorticoid receptor, also reduced expressions of Pref-1 and facilitated intracellular accumulation of lipids.

Conclusions: Our results suggest that fat ingestion-induced release of CORT contributes to adipose expansion and development of obesity and highlight the pathogenic role of CORT-mediated downregulation of adipose Pref-1 in diet-induced obesity.

背景:本研究旨在探讨长期摄入高脂饮食(HFD)诱导的糖皮质激素(GCs)如何介导HFD诱导的脂肪膨胀和肥胖:为了实现这一目标,我们使用了一种独特的 L/L 小鼠模型,该模型在长期摄入高脂饮食后不能诱导皮质酮(CORT)水平,而皮质酮是啮齿类动物体内的一种主要 GCs:结果:我们发现,与野生型小鼠相比,L/L 型小鼠在摄入 12 周高密度脂蛋白后体重增加较少,脂肪膨胀较轻,血浆甘油三酯水平较高。给L/L小鼠补充CORT后,这些变化被逆转。在研究 CORT 诱导的脂肪膨胀过程中与脂质摄取和新脂肪生成相关的各种分子的表达水平时,我们观察到脂肪前脂肪细胞因子 1(Pref-1)的表达减少,而 Pref-1 是脂肪生成的一个关键调节因子。在 3T3-L1 类前脂肪细胞中,糖皮质激素受体激动剂地塞米松也会降低 Pref-1 的表达,并促进脂质在细胞内的积累:我们的研究结果表明,脂肪摄入诱导的 CORT 释放有助于脂肪膨胀和肥胖的发生,并强调了 CORT 介导的脂肪 Pref-1 下调在饮食诱导肥胖中的致病作用。
{"title":"High-fat diet-induced increase in glucocorticoids contributes to adipogenesis in obese mice.","authors":"Sheng-Feng Tsai, Pei-Ling Hsu, Mei-Chen Yeh, Hao-Chang Hung, Monica Meng-Chun Shih, Bon-Chu Chung, Chia-Yih Wang, Chih-Jen Chang, Yu-Min Kuo","doi":"10.1016/j.bj.2024.100772","DOIUrl":"https://doi.org/10.1016/j.bj.2024.100772","url":null,"abstract":"<p><strong>Background: </strong>This study was designed to examine how glucocorticoids (GCs) induced by a long-term ingestion of high-fat diet (HFD) mediate the HFD-induced adipose expansion and obesity.</p><p><strong>Material and methods: </strong>To address this goal, we used a unique L/L mouse model that fails to induce its corticosterone (CORT) level, a major type of GCs in rodents, after prolonged exposure to an HFD.</p><p><strong>Results: </strong>We found that, after receiving a 12-week HFD feeding, the L/L mice show less weight gain, milder adipose expansion, and higher plasma levels of triglycerides than the wild-type mice. These changes were reversed by replenishing CORT to L/L mice. When examining the expression levels of various molecules linked to lipid uptake and de novo lipogenesis in CORT-induced adipose expansion, we observed a reduction in the expression of adipose preadipocyte factor 1 (Pref-1), a key regulator in adipogenesis. In 3T3-L1 preadipocyte-like cells, dexamethasone, an agonist of the glucocorticoid receptor, also reduced expressions of Pref-1 and facilitated intracellular accumulation of lipids.</p><p><strong>Conclusions: </strong>Our results suggest that fat ingestion-induced release of CORT contributes to adipose expansion and development of obesity and highlight the pathogenic role of CORT-mediated downregulation of adipose Pref-1 in diet-induced obesity.</p>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":" ","pages":"100772"},"PeriodicalIF":4.1,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141756990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The establishment of a molecular diagnostic platform for mitochondrial diseases: from conventional to next-generation sequencing. 线粒体疾病分子诊断平台的建立:从传统测序到新一代测序。
IF 4.1 3区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-22 DOI: 10.1016/j.bj.2024.100770
Ni-Chin Tsai, Chai-Wai Liou, Yin-Hua Cheng, Hao-Ting Lien, Tzu-Ling Lin, Tsu-Kung Lin, Min-Yu Lan, Pi-Lien Hung, Tzu-Jou Wang, Chen-Hao Lee, Yi-Chih Liang, Kuo-Chung Lan

Background: The aim of this study was to create a molecular diagnostic platform and establish a diagnostic pipeline for patients highly suspected of mitochondrial disorders. The effectiveness of three methods, namely, traditional restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR), Sanger sequencing for hotspot detection and whole mitochondrial DNA (mtDNA), and third-generation (Nanopore) whole mtDNA sequencing, will be compared in diagnosing patients with suspected primary mitochondrial diseases (PMDs). The strengths and limitations of different methods are also discussed.

Material and methods: A single-center prospective cohort study was conducted to validate the diagnostic pipeline for suspected mitochondrial diseases. In the first stage, a PCR-based method with five sets of primers was used to screen for eight hotspots (m.3243A>G, m.3460G>A, m.8344A>G, m.8993T>G, m.9185T>C, m.11778G>A, m.13513G>A, and m.4977deletion) using either RFLP or direct Sanger sequencing. Sanger sequencing was also used to confirm the RFLP-positive samples. In the second stage, for samples with negative screening results for the eight hotspots, mitochondrial whole-genome sequencing was performed using Sanger sequencing or third-generation nanopore sequencing.

Results: Between June 2020 and May 2023, 30 patients from ages 0 to 63 with clinically suspected mitochondrial disease were enrolled. The positive yield for the diagnosis of PMDs was 8/30=26.7%, and the sensitivity of the heteroplasmy level for the RFLP-based method was approximately 5%. The remaining 22 patients who tested negative at the first stage were tested using Sanger sequencing or the third-generation sequencing Nanopore, and all tested negative for pathological mtDNA mutations. Compared to the Sanger sequencing method, the results of RFLP-PCR were compromised by the limitations of incomplete RFLP enzyme digestion. For whole-genome sequencing of mtDNA, Sanger sequencing, instead of nanopore sequencing, is preferred at our institution because of its cost-effectiveness.

Conclusions: In our highly selective cohort, most tested positive in the first stage of the 8 hot spots screen. Sanger sequencing is a conventional and accurate method for mitochondrial disease screening, at least for the most common hot spots in the region. The results revealed that Sanger sequencing is an accurate method with the benefit of being more cost-effective. This integral platform of molecular diagnosis bears the advantages of being relatively low cost and having a shorter reporting time, facilitating crucial identification of patients with clinical evidence of such disorders. This diagnostic flowchart has also been translated into routine clinical use in the tertiary hospital.

研究背景本研究旨在创建一个分子诊断平台,并为高度怀疑患有线粒体疾病的患者建立诊断管道。研究将比较三种方法,即传统的限制性片段长度多态性聚合酶链反应(RFLP-PCR)、用于热点检测和全线粒体DNA(mtDNA)的桑格测序法以及第三代(Nanopore)全线粒体DNA测序法,在诊断疑似原发性线粒体疾病(PMDs)患者方面的有效性。材料和方法:为了验证疑似线粒体疾病的诊断方法,我们进行了一项单中心前瞻性队列研究。在第一阶段,采用五组引物的 PCR 方法,利用 RFLP 或直接 Sanger 测序筛选八个热点(m.3243A>G、m.3460G>A、m.8344A>G、m.8993T>G、m.9185T>C、m.11778G>A、m.13513G>A 和 m.4977deletion)。Sanger 测序也用于确认 RFLP 阳性样本。在第二阶段,对于八个热点筛选结果呈阴性的样本,采用桑格测序法或第三代纳米孔测序法进行线粒体全基因组测序:结果:2020 年 6 月至 2023 年 5 月期间,30 名临床疑似线粒体疾病的 0 至 63 岁患者入组。PMD诊断的阳性率为8/30=26.7%,基于RFLP方法的异体水平灵敏度约为5%。第一阶段检测结果为阴性的其余22名患者使用桑格测序法或第三代测序法Nanopore进行检测,结果显示所有患者的病理mtDNA突变均为阴性。与桑格测序法相比,RFLP-PCR 的结果受到 RFLP 酶消化不完全的限制。对于mtDNA的全基因组测序,我们机构更倾向于使用桑格测序法,而不是纳米孔测序法,因为它具有成本效益:在我们的高选择性队列中,大多数人在 8 个热点筛查的第一阶段检测中呈阳性。桑格测序是线粒体疾病筛查的一种传统而准确的方法,至少对该地区最常见的热点来说是如此。结果表明,桑格测序是一种准确的方法,而且成本效益更高。这一完整的分子诊断平台具有成本相对较低、报告时间较短的优点,有助于对有临床证据表明患有此类疾病的患者进行重要的鉴定。该诊断流程图也已被转化为三级医院的常规临床应用。
{"title":"The establishment of a molecular diagnostic platform for mitochondrial diseases: from conventional to next-generation sequencing.","authors":"Ni-Chin Tsai, Chai-Wai Liou, Yin-Hua Cheng, Hao-Ting Lien, Tzu-Ling Lin, Tsu-Kung Lin, Min-Yu Lan, Pi-Lien Hung, Tzu-Jou Wang, Chen-Hao Lee, Yi-Chih Liang, Kuo-Chung Lan","doi":"10.1016/j.bj.2024.100770","DOIUrl":"https://doi.org/10.1016/j.bj.2024.100770","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to create a molecular diagnostic platform and establish a diagnostic pipeline for patients highly suspected of mitochondrial disorders. The effectiveness of three methods, namely, traditional restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR), Sanger sequencing for hotspot detection and whole mitochondrial DNA (mtDNA), and third-generation (Nanopore) whole mtDNA sequencing, will be compared in diagnosing patients with suspected primary mitochondrial diseases (PMDs). The strengths and limitations of different methods are also discussed.</p><p><strong>Material and methods: </strong>A single-center prospective cohort study was conducted to validate the diagnostic pipeline for suspected mitochondrial diseases. In the first stage, a PCR-based method with five sets of primers was used to screen for eight hotspots (m.3243A>G, m.3460G>A, m.8344A>G, m.8993T>G, m.9185T>C, m.11778G>A, m.13513G>A, and m.4977deletion) using either RFLP or direct Sanger sequencing. Sanger sequencing was also used to confirm the RFLP-positive samples. In the second stage, for samples with negative screening results for the eight hotspots, mitochondrial whole-genome sequencing was performed using Sanger sequencing or third-generation nanopore sequencing.</p><p><strong>Results: </strong>Between June 2020 and May 2023, 30 patients from ages 0 to 63 with clinically suspected mitochondrial disease were enrolled. The positive yield for the diagnosis of PMDs was 8/30=26.7%, and the sensitivity of the heteroplasmy level for the RFLP-based method was approximately 5%. The remaining 22 patients who tested negative at the first stage were tested using Sanger sequencing or the third-generation sequencing Nanopore, and all tested negative for pathological mtDNA mutations. Compared to the Sanger sequencing method, the results of RFLP-PCR were compromised by the limitations of incomplete RFLP enzyme digestion. For whole-genome sequencing of mtDNA, Sanger sequencing, instead of nanopore sequencing, is preferred at our institution because of its cost-effectiveness.</p><p><strong>Conclusions: </strong>In our highly selective cohort, most tested positive in the first stage of the 8 hot spots screen. Sanger sequencing is a conventional and accurate method for mitochondrial disease screening, at least for the most common hot spots in the region. The results revealed that Sanger sequencing is an accurate method with the benefit of being more cost-effective. This integral platform of molecular diagnosis bears the advantages of being relatively low cost and having a shorter reporting time, facilitating crucial identification of patients with clinical evidence of such disorders. This diagnostic flowchart has also been translated into routine clinical use in the tertiary hospital.</p>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":" ","pages":"100770"},"PeriodicalIF":4.1,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141756991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between Pentoxifylline Use and Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Multi-Institutional Cohort Study. 2 型糖尿病合并慢性肾脏病患者使用五氧嘧啶与糖尿病视网膜病变之间的关系:一项多机构队列研究。
IF 4.1 3区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-19 DOI: 10.1016/j.bj.2024.100771
Tzu-Yi Lin, Eugene Yu-Chuan Kang, Nan-Kai Wang, Je-Ho Kang, Kuan-Jen Chen, Wei-Chi Wu, Chi-Chun Lai, Yih-Shiou Hwang

Background: Pentoxifylline is administrated to improve the hemodynamics of patients with chronic kidney disease (CKD). Despite the improvement of capillary blood flow velocity in retina after pentoxifylline use, no evidence has been provided to prove the protective effect for diabetic retinopathy (DR). Therefore, this study aimed to assess the risk of DR in pentoxifylline users with CKD and diabetes mellitus (DM).

Material and methods: In this retrospective cohort study, Chang Gung Research Database, which includes the data of patients with CKD and DM from 2003 to 2019, was used. Each calendar year was divided into 4 data units with 3 months each for every patient and every year during the follow-up. The ocular outcomes were new-onset DR, DR-related complications, and vitreoretinal interventions.

Results: Total 56,439 patients without preexisting DR and 5,039 patients with preexisting DR were included in this study. Exposure to pentoxifylline was associated with elevated risk of new-onset DR (adjusted hazard ratio = 1.24, 95% confidence interval = 1.13-1.36) in patients without preexisting DR. Additionally, exposure to pentoxifylline was associated with elevated risk of DR-related complications and vitreoretinal interventions in patients with or without preexisting DR.

Conclusions: Exposure to pentoxifylline is associated with elevated risk of DR, regardless of whether patients have preexisting DR.

背景:使用五氧去氧肾上腺素可改善慢性肾脏病(CKD)患者的血液动力学。尽管使用五氧去氧肾上腺素后视网膜毛细血管血流速度有所改善,但尚无证据证明其对糖尿病视网膜病变(DR)有保护作用。因此,本研究旨在评估患有慢性肾脏病和糖尿病(DM)的戊唑醇使用者发生 DR 的风险:在这项回顾性队列研究中,使用了长庚研究数据库,其中包括 2003 年至 2019 年期间 CKD 和 DM 患者的数据。在随访期间,每个日历年分为 4 个数据单元,每个单元为每个患者和每年 3 个月。眼部结果包括新发 DR、DR 相关并发症和玻璃体视网膜干预:本研究共纳入了 56439 名未患 DR 的患者和 5039 名已患 DR 的患者。在无原有 DR 的患者中,接触戊氧地塞米松与新发 DR 风险升高有关(调整后危险比 = 1.24,95% 置信区间 = 1.13-1.36)。此外,无论是否已存在DR,暴露于戊氧肾上腺素均与DR相关并发症和玻璃体视网膜干预风险升高有关:结论:无论患者是否患有先天性DR,接触戊乙福林都与DR风险升高有关。
{"title":"Association Between Pentoxifylline Use and Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Multi-Institutional Cohort Study.","authors":"Tzu-Yi Lin, Eugene Yu-Chuan Kang, Nan-Kai Wang, Je-Ho Kang, Kuan-Jen Chen, Wei-Chi Wu, Chi-Chun Lai, Yih-Shiou Hwang","doi":"10.1016/j.bj.2024.100771","DOIUrl":"https://doi.org/10.1016/j.bj.2024.100771","url":null,"abstract":"<p><strong>Background: </strong>Pentoxifylline is administrated to improve the hemodynamics of patients with chronic kidney disease (CKD). Despite the improvement of capillary blood flow velocity in retina after pentoxifylline use, no evidence has been provided to prove the protective effect for diabetic retinopathy (DR). Therefore, this study aimed to assess the risk of DR in pentoxifylline users with CKD and diabetes mellitus (DM).</p><p><strong>Material and methods: </strong>In this retrospective cohort study, Chang Gung Research Database, which includes the data of patients with CKD and DM from 2003 to 2019, was used. Each calendar year was divided into 4 data units with 3 months each for every patient and every year during the follow-up. The ocular outcomes were new-onset DR, DR-related complications, and vitreoretinal interventions.</p><p><strong>Results: </strong>Total 56,439 patients without preexisting DR and 5,039 patients with preexisting DR were included in this study. Exposure to pentoxifylline was associated with elevated risk of new-onset DR (adjusted hazard ratio = 1.24, 95% confidence interval = 1.13-1.36) in patients without preexisting DR. Additionally, exposure to pentoxifylline was associated with elevated risk of DR-related complications and vitreoretinal interventions in patients with or without preexisting DR.</p><p><strong>Conclusions: </strong>Exposure to pentoxifylline is associated with elevated risk of DR, regardless of whether patients have preexisting DR.</p>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":" ","pages":"100771"},"PeriodicalIF":4.1,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141733498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Which outcomes are key to the pre-intervention assessment profile of a child with developmental coordination disorder? A systematic review and meta-analysis. 哪些结果是发育协调障碍儿童干预前评估概况的关键?系统回顾与荟萃分析。
IF 4.1 3区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-18 DOI: 10.1016/j.bj.2024.100768
Bouwien Smits-Engelsman, Marisja Denysschen, Jessica Lust, Dané Coetzee, Ludvik Valtr, Marina Schoemaker, Evi Verbecque

Background: Purpose of this study was to determine what key aspects of function should be incorporated to make up a pre-intervention assessment profile of a child with Developmental Coordination Disorder (DCD); more specifically, what aspects of functioning are implicated in DCD and what is their relative impact?

Methods: A systematic review and meta-analysis were conducted, for which Pubmed, Web of Science, Scopus and Proquest were searched (last update: April 2023, PROSPERO: CRD42023461619). Case-control studies were included to determine point estimates for performances on field-based tests in different domains of functioning. Risk of bias was assessed, and level of evidence estimated. Random-effect meta-analyses were performed to calculate the pooled standardized mean differences for domains of functioning and subgrouping was done for clinically relevant subdomains. Heterogeneity was determined with I2.

Results: 121 papers were included for analyses. Data of 5 923 children with DCD were included (59.8% boys) and 23 619 Typically Developing (TD) children (45.8% boys). The mean (SD) age of the DCD group was 10.3y (1.2) and 9.3y (1.3) for the TD children. Moderate evidence was found for motor performance, executive functions, sensory processing and perceptions, cognitive functions and sports and leisure activities to be affected in children with DCD.

Conclusion: Differences between the two groups varied per domain of functioning. This emphasizes the diversity present within children with DCD and provides a rationale for explaining the heterogeneity in this patient group. Yet, results highlight the potential involvement of all these domains and call for clinicians to be alert not only to examine motor skill difficulties but also other aspects of function. Results indicate the need to develop an individualized pre-intervention multi-dimensional assessment profile for each child with DCD. It also supports the important role that clinicians play in an interdisciplinary team to tackle the difficulties encountered by children with DCD.

研究背景本研究的目的是确定在对发育协调障碍(DCD)儿童进行干预前评估时,应纳入哪些关键的功能方面;更具体地说,哪些功能方面与 DCD 有关,以及它们的相对影响是什么?对 Pubmed、Web of Science、Scopus 和 Proquest 进行了系统回顾和荟萃分析(最后更新时间:2023 年 4 月,PROSPERO:CRD42023461619)。其中包括病例对照研究,以确定不同功能领域的现场测试表现的点估计值。对偏倚风险进行了评估,并对证据水平进行了估计。进行随机效应荟萃分析以计算功能领域的集合标准化均值差异,并对临床相关的子领域进行分组。异质性用I2确定:共纳入 121 篇论文进行分析。共纳入了 5 923 名患有 DCD 的儿童(59.8% 为男孩)和 23 619 名发育正常(TD)儿童(45.8% 为男孩)的数据。DCD 组儿童的平均(标清)年龄为 10.3 岁(1.2),TD 组儿童的平均(标清)年龄为 9.3 岁(1.3)。研究发现,中等程度的证据表明,DCD儿童的运动表现、执行功能、感觉处理和知觉、认知功能以及运动和休闲活动会受到影响:结论:两组儿童在各个功能领域的差异各不相同。这强调了 DCD 儿童的多样性,并为解释这一患者群体的异质性提供了理论依据。然而,研究结果强调了所有这些领域的潜在参与性,并呼吁临床医生不仅要警惕运动技能方面的困难,还要注意功能的其他方面。研究结果表明,有必要为每名儿童发育迟缓症患者制定个性化的干预前多维评估档案。它还支持临床医生在跨学科团队中发挥重要作用,以解决 DCD 儿童遇到的困难。
{"title":"Which outcomes are key to the pre-intervention assessment profile of a child with developmental coordination disorder? A systematic review and meta-analysis.","authors":"Bouwien Smits-Engelsman, Marisja Denysschen, Jessica Lust, Dané Coetzee, Ludvik Valtr, Marina Schoemaker, Evi Verbecque","doi":"10.1016/j.bj.2024.100768","DOIUrl":"https://doi.org/10.1016/j.bj.2024.100768","url":null,"abstract":"<p><strong>Background: </strong>Purpose of this study was to determine what key aspects of function should be incorporated to make up a pre-intervention assessment profile of a child with Developmental Coordination Disorder (DCD); more specifically, what aspects of functioning are implicated in DCD and what is their relative impact?</p><p><strong>Methods: </strong>A systematic review and meta-analysis were conducted, for which Pubmed, Web of Science, Scopus and Proquest were searched (last update: April 2023, PROSPERO: CRD42023461619). Case-control studies were included to determine point estimates for performances on field-based tests in different domains of functioning. Risk of bias was assessed, and level of evidence estimated. Random-effect meta-analyses were performed to calculate the pooled standardized mean differences for domains of functioning and subgrouping was done for clinically relevant subdomains. Heterogeneity was determined with I<sup>2</sup>.</p><p><strong>Results: </strong>121 papers were included for analyses. Data of 5 923 children with DCD were included (59.8% boys) and 23 619 Typically Developing (TD) children (45.8% boys). The mean (SD) age of the DCD group was 10.3y (1.2) and 9.3y (1.3) for the TD children. Moderate evidence was found for motor performance, executive functions, sensory processing and perceptions, cognitive functions and sports and leisure activities to be affected in children with DCD.</p><p><strong>Conclusion: </strong>Differences between the two groups varied per domain of functioning. This emphasizes the diversity present within children with DCD and provides a rationale for explaining the heterogeneity in this patient group. Yet, results highlight the potential involvement of all these domains and call for clinicians to be alert not only to examine motor skill difficulties but also other aspects of function. Results indicate the need to develop an individualized pre-intervention multi-dimensional assessment profile for each child with DCD. It also supports the important role that clinicians play in an interdisciplinary team to tackle the difficulties encountered by children with DCD.</p>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":" ","pages":"100768"},"PeriodicalIF":4.1,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141733499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fecal miRNAs as potential biomarkers for early detection of colorectal cancer: An updated review. 粪便 miRNAs 作为早期检测结直肠癌的潜在生物标记物:最新综述。
IF 4.1 3区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-16 DOI: 10.1016/j.bj.2024.100769
Chia-Chun Chen, Pi-Yueh Chang
{"title":"Fecal miRNAs as potential biomarkers for early detection of colorectal cancer: An updated review.","authors":"Chia-Chun Chen, Pi-Yueh Chang","doi":"10.1016/j.bj.2024.100769","DOIUrl":"https://doi.org/10.1016/j.bj.2024.100769","url":null,"abstract":"","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":" ","pages":"100769"},"PeriodicalIF":4.1,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141722992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Basic implications on three pathways associated with SARS-CoV-2. 与 SARS-CoV-2 有关的三条途径的基本含义。
IF 4.1 3区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-14 DOI: 10.1016/j.bj.2024.100766
Jong Hoon Lee, Consolato Sergi, Richard E Kast, Badar A Kanwar, Jean Bourbeau, Sangsuk Oh, Mun-Gi Sohn, Chul Joong Lee, Michael D Coleman

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) interacts between the host and virus and govern induction, resulting in multiorgan impacts. Its pathophysiology involves the followings: 1) the angiotensin-converting enzyme (ACE2) and Toll-like receptor (TLR) pathways: 2) the neuropilin (NRP) pathway: 3) the spike protein pathway. Therefore, it is necessary to block the pathological course with modulating innate lymphoid cells against diverse corona variants in the future.

严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)在宿主和病毒之间相互作用并进行诱导,造成多器官影响。其病理生理学涉及以下几个方面:1) 血管紧张素转换酶(ACE2)和 Toll 样受体(TLR)途径:2) 神经蛋白(NRP)途径:3) 穗状蛋白途径。因此,今后有必要通过调节先天性淋巴细胞来阻断病理过程,以抵御各种日冕变异体。
{"title":"Basic implications on three pathways associated with SARS-CoV-2.","authors":"Jong Hoon Lee, Consolato Sergi, Richard E Kast, Badar A Kanwar, Jean Bourbeau, Sangsuk Oh, Mun-Gi Sohn, Chul Joong Lee, Michael D Coleman","doi":"10.1016/j.bj.2024.100766","DOIUrl":"10.1016/j.bj.2024.100766","url":null,"abstract":"<p><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) interacts between the host and virus and govern induction, resulting in multiorgan impacts. Its pathophysiology involves the followings: 1) the angiotensin-converting enzyme (ACE2) and Toll-like receptor (TLR) pathways: 2) the neuropilin (NRP) pathway: 3) the spike protein pathway. Therefore, it is necessary to block the pathological course with modulating innate lymphoid cells against diverse corona variants in the future.</p>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":" ","pages":"100766"},"PeriodicalIF":4.1,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141615886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Activating transcription factor 3 is an antitumor gene synergizing with growth differentiation factor 15 to modulate cell growth in human bladder cancer. 激活转录因子 3 是一种抗肿瘤基因,可与生长分化因子 15 协同调节人类膀胱癌细胞的生长。
IF 4.1 3区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-06-26 DOI: 10.1016/j.bj.2024.100756
Syue-Ting Chen, Kang-Shuo Chang, Wei-Yin Lin, Shu-Yuan Hsu, Hsin-Ching Sung, Yu-Hsiang Lin, Tsui-Hsia Feng, Chen-Pang Hou, Horng-Heng Juang

Background: The functions of activating transcription factor 3 (ATF3) within the human bladder remain unexplored. This study delves into the expressions, functions, and regulatory mechanisms of ATF3 in human bladder cancer.

Material and methods: Gene expressions were determined by immunoblot, RT-qPCR, and reporter assays. Assays of Ki67, colony formation, Matrigel invasion, and the xenograft animal study were used to assess the cell proliferation, invasion, and tumorigenesis in vitro and in vivo. Silico analysis from TCGA database examined the correlations between GDF15 and ATF3 expressions, clinicopathologic features, and progression-free survival rates.

Results: Silico analysis confirmed that ATF3 is an antitumor gene, and the expression positively correlates with GDF15 in bladder cancer tissues. Multivariate analysis revealed that low ATF3/GDF15 but not a single low expression of ATF3 is an independent prognostic factor for progression-free survival of bladder cancer patients. Ectopic overexpression of ATF3 downregulated cell proliferation and invasion in bladder cancer cells in vitro, while ATF3-knockdown reversed these results. Knockdown of ATF3 upregulated EMT markers to enhance cell invasion in vitro and downregulated GDF15, NDRG1, and KAI-1 to elevate tumor growth in vivo. The activation of metformin on ATF3 and GDF15 in bladder cancer cells was blocked by SB431542, a TGFβ receptor inhibitor. ATF3 positively regulated GDF15 expression in bladder cancer cells through a feedback loop.

Conclusions: Our results identify that ATF3 is a metformin-upregulated antitumor gene. Results of Silico analysis align with cell-based studies suggesting that low ATF3/GDF15 could be a negative prognostic marker for bladder cancer.

背景:活化转录因子3(ATF3)在人类膀胱中的功能仍有待探索。本研究探讨了 ATF3 在人类膀胱癌中的表达、功能和调控机制:通过免疫印迹、RT-qPCR 和报告基因检测确定基因表达。Ki67、集落形成、Matrigel侵袭和异种动物实验用于评估体外和体内的细胞增殖、侵袭和肿瘤发生。来自TCGA数据库的Silico分析检验了GDF15和ATF3表达、临床病理特征和无进展生存率之间的相关性:结果:Silico分析证实,ATF3是一种抗肿瘤基因,其在膀胱癌组织中的表达与GDF15呈正相关。多变量分析显示,ATF3/GDF15的低表达是膀胱癌患者无进展生存期的独立预后因素,而非单一的低表达。体外异位过表达 ATF3 会降低膀胱癌细胞的增殖和侵袭,而敲除 ATF3 则会逆转这些结果。敲除ATF3会上调EMT标记物,从而增强体外细胞侵袭,并下调GDF15、NDRG1和KAI-1,从而促进体内肿瘤生长。二甲双胍对膀胱癌细胞中ATF3和GDF15的激活作用被TGFβ受体抑制剂SB431542阻断。ATF3通过反馈环路正向调节膀胱癌细胞中GDF15的表达:我们的研究结果表明,ATF3 是二甲双胍上调的抗肿瘤基因。Silico分析结果与基于细胞的研究结果一致,表明低ATF3/GDF15可能是膀胱癌的一个负面预后标志。
{"title":"Activating transcription factor 3 is an antitumor gene synergizing with growth differentiation factor 15 to modulate cell growth in human bladder cancer.","authors":"Syue-Ting Chen, Kang-Shuo Chang, Wei-Yin Lin, Shu-Yuan Hsu, Hsin-Ching Sung, Yu-Hsiang Lin, Tsui-Hsia Feng, Chen-Pang Hou, Horng-Heng Juang","doi":"10.1016/j.bj.2024.100756","DOIUrl":"https://doi.org/10.1016/j.bj.2024.100756","url":null,"abstract":"<p><strong>Background: </strong>The functions of activating transcription factor 3 (ATF3) within the human bladder remain unexplored. This study delves into the expressions, functions, and regulatory mechanisms of ATF3 in human bladder cancer.</p><p><strong>Material and methods: </strong>Gene expressions were determined by immunoblot, RT-qPCR, and reporter assays. Assays of Ki67, colony formation, Matrigel invasion, and the xenograft animal study were used to assess the cell proliferation, invasion, and tumorigenesis in vitro and in vivo. Silico analysis from TCGA database examined the correlations between GDF15 and ATF3 expressions, clinicopathologic features, and progression-free survival rates.</p><p><strong>Results: </strong>Silico analysis confirmed that ATF3 is an antitumor gene, and the expression positively correlates with GDF15 in bladder cancer tissues. Multivariate analysis revealed that low ATF3/GDF15 but not a single low expression of ATF3 is an independent prognostic factor for progression-free survival of bladder cancer patients. Ectopic overexpression of ATF3 downregulated cell proliferation and invasion in bladder cancer cells in vitro, while ATF3-knockdown reversed these results. Knockdown of ATF3 upregulated EMT markers to enhance cell invasion in vitro and downregulated GDF15, NDRG1, and KAI-1 to elevate tumor growth in vivo. The activation of metformin on ATF3 and GDF15 in bladder cancer cells was blocked by SB431542, a TGFβ receptor inhibitor. ATF3 positively regulated GDF15 expression in bladder cancer cells through a feedback loop.</p><p><strong>Conclusions: </strong>Our results identify that ATF3 is a metformin-upregulated antitumor gene. Results of Silico analysis align with cell-based studies suggesting that low ATF3/GDF15 could be a negative prognostic marker for bladder cancer.</p>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":" ","pages":"100756"},"PeriodicalIF":4.1,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141466003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liver transplantation for advanced hepatocellular carcinoma: Controversy over portal vein tumor thrombosis. 晚期肝细胞癌肝移植:关于门静脉肿瘤血栓的争议。
IF 4.1 3区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-06-26 DOI: 10.1016/j.bj.2024.100757
Kun-Ming Chan, Wei-Chen Lee

Liver transplantation (LT) is considered the ideal treatment for hepatocellular carcinoma (HCC) concurrent with underlying cirrhotic liver disease. As well-known, LT for HCC based on the Milan criteria has shown satisfactory outcomes. However, numerous expanded transplantation criteria were proposed to benefit more patients for LT and showed comparable survivals as well. In addition, a modest expansion of transplantation criteria for HCC may be acceptable on the basis of the consensus within the transplantation community. Nonetheless, LT in patients with advanced HCC and portal vein tumor thrombosis (PVTT) recently has received attention and has been reported by many transplantation centers despite being contraindicated. Of those, the LT outcomes in certain HCC patients with PVTT were favorable. Additionally, the advancement of multimodality treatments and the evolution of systemic therapies have emerged as promising therapeutic options for downstaging advanced HCC prior to LT. Somehow, advanced HCC with PVTT could be downstaged to become eligible for LT through these multidisciplinary approaches. Although the available evidence of LT for HCC with PVTT is limited, it is hoped that LT may soon be more widely indicated for these patients. Nevertheless, several unknown factors associated with LT for HCC remain to be explored. Herein, this review aimed to update the developments in LT for patients with advanced HCC.

肝移植(LT)被认为是治疗并发肝硬化的肝细胞癌(HCC)的理想方法。众所周知,以米兰标准为基础的肝癌LT治疗效果令人满意。然而,为了让更多患者受益于LT治疗,许多扩大移植标准被提出,并显示出相当的存活率。此外,根据移植界的共识,适度扩大 HCC 移植标准也是可以接受的。尽管如此,晚期 HCC 和门静脉肿瘤血栓形成(PVTT)患者的 LT 近来受到了关注,尽管有禁忌症,但许多移植中心仍有相关报道。其中,某些伴有门静脉瘤栓形成的 HCC 患者的 LT 结果良好。此外,多模式疗法的发展和全身疗法的演变已成为在 LT 前对晚期 HCC 进行分期的有前途的治疗方案。通过这些多学科方法,晚期HCC伴PVTT患者可以通过降期治疗获得LT治疗资格。尽管现有证据表明LT治疗伴有PVTT的HCC的效果有限,但我们希望LT能在不久的将来更广泛地应用于这些患者。尽管如此,仍有一些与 HCC LT 相关的未知因素有待探索。本综述旨在介绍晚期 HCC 患者 LT 的最新进展。
{"title":"Liver transplantation for advanced hepatocellular carcinoma: Controversy over portal vein tumor thrombosis.","authors":"Kun-Ming Chan, Wei-Chen Lee","doi":"10.1016/j.bj.2024.100757","DOIUrl":"https://doi.org/10.1016/j.bj.2024.100757","url":null,"abstract":"<p><p>Liver transplantation (LT) is considered the ideal treatment for hepatocellular carcinoma (HCC) concurrent with underlying cirrhotic liver disease. As well-known, LT for HCC based on the Milan criteria has shown satisfactory outcomes. However, numerous expanded transplantation criteria were proposed to benefit more patients for LT and showed comparable survivals as well. In addition, a modest expansion of transplantation criteria for HCC may be acceptable on the basis of the consensus within the transplantation community. Nonetheless, LT in patients with advanced HCC and portal vein tumor thrombosis (PVTT) recently has received attention and has been reported by many transplantation centers despite being contraindicated. Of those, the LT outcomes in certain HCC patients with PVTT were favorable. Additionally, the advancement of multimodality treatments and the evolution of systemic therapies have emerged as promising therapeutic options for downstaging advanced HCC prior to LT. Somehow, advanced HCC with PVTT could be downstaged to become eligible for LT through these multidisciplinary approaches. Although the available evidence of LT for HCC with PVTT is limited, it is hoped that LT may soon be more widely indicated for these patients. Nevertheless, several unknown factors associated with LT for HCC remain to be explored. Herein, this review aimed to update the developments in LT for patients with advanced HCC.</p>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":" ","pages":"100757"},"PeriodicalIF":4.1,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141466004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronobioethics: Symphony of biological clocks observed by 7-day/24-hour ambulatory blood pressure monitoring and cardiovascular health. 时间生物伦理学:通过 7 天/24 小时动态血压监测观察到的生物钟交响乐与心血管健康。
IF 4.1 3区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-06-19 DOI: 10.1016/j.bj.2024.100753
Kuniaki Otsuka, Larry A Beaty, Madoka Sato, Kazunobu Shitakura, Tomoko Kikuchi, Kiyotaka Okajima, Shigehiko Terada, Germaine Cornelissen

Background: The high prevalence of desynchronized biological rhythms is becoming a primary public health concern. We assess complex and diverse inter-modulations among multi-frequency rhythms present in blood pressure (BP) and heart rate (HR).

Subjects: and Methods: We performed 7-day/24-hour Ambulatory BP Monitoring in 220 (133 women) residents (23 to 74 years) of a rural Japanese town in Kochi Prefecture under everyday life conditions.

Results: A symphony of biological clocks contributes to the preservation of a synchronized circadian system. (1) Citizens with an average 12.02-h period had fewer vascular variability disorders than those with shorter (11.37-h) or longer (12.88-h) periods (P<0.05), suggesting that the circasemidian rhythm is potentially important for human health. (2) An appropriate BP-HR coupling promoted healthier circadian profiles than a phase-advanced BP: lower 7-day nighttime SBP (106.8 vs. 112.9 mmHg, P=0.0469), deeper nocturnal SBP dip (20.5% vs. 16.8%, P=0.0101), and less frequent incidence of masked non-dipping (0.53 vs. 0.86, P=0.0378), identifying the night as an important time window.

Conclusion: Adaptation to irregular schedules in everyday life occurs unconsciously at night, probably initiated from the brain default mode network, in coordination with the biological clock system, including a reinforced about 12-hour clock, as "a biological clock-guided core integration system".

背景:不同步生物节律的高发生率正成为公共健康的首要问题。我们评估了血压(BP)和心率(HR)中多频节律之间复杂多样的相互调制:我们对高知县一个日本农村小镇的 220 名居民(133 名女性)(23 至 74 岁)进行了日常生活条件下的 7 天/24 小时动态血压监测:生物钟的交响乐有助于保持昼夜节律系统的同步。(1) 与昼夜节律较短(11.37 小时)或较长(12.88 小时)的人相比,平均昼夜节律为 12.02 小时的人患血管变异性疾病的几率较低(结论:昼夜节律不规律的生活适应性有助于保持昼夜节律系统的同步:对日常生活中不规则时间安排的适应是在夜间无意识地发生的,可能是由大脑默认模式网络与生物钟系统(包括强化的约 12 小时时钟)协调启动的,是 "生物钟引导的核心整合系统"。
{"title":"Chronobioethics: Symphony of biological clocks observed by 7-day/24-hour ambulatory blood pressure monitoring and cardiovascular health.","authors":"Kuniaki Otsuka, Larry A Beaty, Madoka Sato, Kazunobu Shitakura, Tomoko Kikuchi, Kiyotaka Okajima, Shigehiko Terada, Germaine Cornelissen","doi":"10.1016/j.bj.2024.100753","DOIUrl":"https://doi.org/10.1016/j.bj.2024.100753","url":null,"abstract":"<p><strong>Background: </strong>The high prevalence of desynchronized biological rhythms is becoming a primary public health concern. We assess complex and diverse inter-modulations among multi-frequency rhythms present in blood pressure (BP) and heart rate (HR).</p><p><strong>Subjects: </strong>and Methods: We performed 7-day/24-hour Ambulatory BP Monitoring in 220 (133 women) residents (23 to 74 years) of a rural Japanese town in Kochi Prefecture under everyday life conditions.</p><p><strong>Results: </strong>A symphony of biological clocks contributes to the preservation of a synchronized circadian system. (1) Citizens with an average 12.02-h period had fewer vascular variability disorders than those with shorter (11.37-h) or longer (12.88-h) periods (P<0.05), suggesting that the circasemidian rhythm is potentially important for human health. (2) An appropriate BP-HR coupling promoted healthier circadian profiles than a phase-advanced BP: lower 7-day nighttime SBP (106.8 vs. 112.9 mmHg, P=0.0469), deeper nocturnal SBP dip (20.5% vs. 16.8%, P=0.0101), and less frequent incidence of masked non-dipping (0.53 vs. 0.86, P=0.0378), identifying the night as an important time window.</p><p><strong>Conclusion: </strong>Adaptation to irregular schedules in everyday life occurs unconsciously at night, probably initiated from the brain default mode network, in coordination with the biological clock system, including a reinforced about 12-hour clock, as \"a biological clock-guided core integration system\".</p>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":" ","pages":"100753"},"PeriodicalIF":4.1,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-throughput Proteomics-Guided Biomarker Discovery of Hepatocellular Carcinoma. 高通量蛋白质组学引导下的肝细胞癌生物标志物发现。
IF 4.1 3区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-06-18 DOI: 10.1016/j.bj.2024.100752
Dongyoon Shin, Yeongshin Kim, Junho Park, Youngsoo Kim

Liver cancer stands as the fifth leading cause of cancer-related deaths globally. Hepatocellular carcinoma (HCC) comprises approximately 85%-90% of all primary liver malignancies. However, only 20-30% of HCC patients qualify for curative therapy, primarily due to the absence of reliable tools for early detection and prognosis of HCC. This underscores the critical need for molecular biomarkers for HCC management. Since proteins reflect disease status directly, proteomics has been utilized in biomarker developments for HCC. In particular, proteomics coupled with liquid chromatography-mass spectrometer (LC-MS) methods facilitate the process of discovering biomarker candidates for diagnosis, prognosis, and therapeutic strategies. In this work, we investigated LC-MS-based proteomics methods through recent reference reviews, with a particular focus on sample preparation and LC-MS methods appropriate for the discovery of HCC biomarkers and their clinical applications. We classified proteomics studies of HCC according to sample types, and we examined the coverage of protein biomarker candidates based on LC-MS methods in relation to study scales and goals. Comprehensively, we proposed protein biomarker candidates categorized by sample types and biomarker types for appropriate clinical use. In this review, we summarized recent LC-MS-based proteomics studies on HCC and proposed potential protein biomarkers. Our findings are expected to expand the understanding of HCC pathogenesis and enhance the efficiency of HCC diagnosis and prognosis, thereby contributing to improved patient outcomes.

肝癌是全球癌症相关死亡的第五大主要原因。肝细胞癌(HCC)约占所有原发性肝脏恶性肿瘤的85%-90%。然而,只有 20%-30% 的 HCC 患者有资格接受根治性治疗,这主要是由于缺乏可靠的 HCC 早期检测和预后工具。这凸显了HCC治疗对分子生物标志物的迫切需要。由于蛋白质能直接反映疾病状态,因此蛋白质组学已被用于 HCC 生物标志物的开发。特别是,蛋白质组学与液相色谱-质谱联用(LC-MS)方法有助于发现用于诊断、预后和治疗策略的候选生物标记物。在这项工作中,我们通过最近的参考文献综述研究了基于液相色谱-质谱的蛋白质组学方法,尤其关注适合发现 HCC 生物标志物及其临床应用的样品制备和液相色谱-质谱方法。我们根据样本类型对 HCC 蛋白质组学研究进行了分类,并结合研究规模和目标考察了基于 LC-MS 方法的候选蛋白质生物标志物的覆盖范围。综上所述,我们提出了按样本类型和生物标记物类型分类的候选蛋白质生物标记物,以供临床使用。在这篇综述中,我们总结了近期基于 LC-MS 的 HCC 蛋白质组学研究,并提出了潜在的蛋白质生物标记物。我们的研究结果有望拓展人们对 HCC 发病机制的认识,提高 HCC 诊断和预后的效率,从而改善患者的预后。
{"title":"High-throughput Proteomics-Guided Biomarker Discovery of Hepatocellular Carcinoma.","authors":"Dongyoon Shin, Yeongshin Kim, Junho Park, Youngsoo Kim","doi":"10.1016/j.bj.2024.100752","DOIUrl":"https://doi.org/10.1016/j.bj.2024.100752","url":null,"abstract":"<p><p>Liver cancer stands as the fifth leading cause of cancer-related deaths globally. Hepatocellular carcinoma (HCC) comprises approximately 85%-90% of all primary liver malignancies. However, only 20-30% of HCC patients qualify for curative therapy, primarily due to the absence of reliable tools for early detection and prognosis of HCC. This underscores the critical need for molecular biomarkers for HCC management. Since proteins reflect disease status directly, proteomics has been utilized in biomarker developments for HCC. In particular, proteomics coupled with liquid chromatography-mass spectrometer (LC-MS) methods facilitate the process of discovering biomarker candidates for diagnosis, prognosis, and therapeutic strategies. In this work, we investigated LC-MS-based proteomics methods through recent reference reviews, with a particular focus on sample preparation and LC-MS methods appropriate for the discovery of HCC biomarkers and their clinical applications. We classified proteomics studies of HCC according to sample types, and we examined the coverage of protein biomarker candidates based on LC-MS methods in relation to study scales and goals. Comprehensively, we proposed protein biomarker candidates categorized by sample types and biomarker types for appropriate clinical use. In this review, we summarized recent LC-MS-based proteomics studies on HCC and proposed potential protein biomarkers. Our findings are expected to expand the understanding of HCC pathogenesis and enhance the efficiency of HCC diagnosis and prognosis, thereby contributing to improved patient outcomes.</p>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":" ","pages":"100752"},"PeriodicalIF":4.1,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Biomedical Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1